Fig. 3

Serotonin upregulated L1CAM signaling to regulate glioma progression. A Heatmap of top 30 overexpressing genes in TPH-1^high glioma patients (n = 49) in comparison with TPH-1^low glioma patients (n = 50). B GO enrichment analysis in TPH-1^high glioma patients (n = 49) in comparison with TPH-1^low glioma patients (n = 50). C western blotting of L1CAM in LN229/T98G cells treated with PBS or serotonin (10 nM), and TPH-1 overexpressing LN229/T98G cells. D relative expression of L1CAM in LN229/T98G cells treated with scrambled and L1CAM siRNA, determined by qPCR. E cell proliferation of PBS cultured LN229/T98G (scrambled siRNA treatment), serotonin (10 nM) cultured LN229/T98G cells treated with scrambled and L1CAM siRNA. F relative migrating cells of PBS cultured LN229/T98G (scrambled siRNA treatment), serotonin (10 nM) cultured LN229/T98G cells treated with scrambled and L1CAM siRNA. G PBS cultured LN229/T98G (scrambled siRNA treatment) was collected, and serotonin (10 nM) cultured LN229/T98G cells were pre-treated with scrambled and L1CAM siRNA. Then cell apoptosis of LN229/T98G treated with PBS or TMZ (1 μg/ml, 48 h) were determined. H overall survival of glioma patients with high L1CAM (n = 49) and low L1CAM (n = 50) expression